Minretumomab
radiolabelled) | |
---|---|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
(what is this?) (verify) |
Minretumomab (CC49) is a
Phase I clinical trials for this purpose.[4]
Derivatives
A wide range of derivatives has been used in pharmaceutical research. Examples include chimeric[5] and humanized minretumomab,[6] as well as a fusion protein of a minretumomab single-chain variable fragment and the enzyme beta-lactamase.[7]
Radiopharmaceuticals
Iodine (125I) minretumomab is an
CA 72-4.[8]
Radiolabelled minretumomab has also been tested for the treatment of solid tumours, but without success. Iodine (
clinical trials.[5]
References
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 13 (3). 1999.
- ^ "TAG-72 antigen". NCI Dictionary of Cancer Terms. National Cancer Institute. 2011-02-02.
- S2CID 205469234.
- ^ "Studies found for: CC49". ClinicalTrials.gov.
- ^ ISBN 0-7637-1428-3.
- PMID 20127951.
- PMID 16536473.
- PMID 8912871.